

FIGURE 1

TRP C11 VECTOR





FIGURE 2







FIGURE 5











FIGURE 6






















FIG 13





Before activation


CD3 mAbs












Anergizec cells


IL-2 R α (CD25)

FIG 14B


Before activation




CD3 mAbs




CD3 mAbs +IL-2




Control cells






Anergized cells


IL-2 R α (CD25)



Añergy can be reversed by high doses of anti-CD3 mAb



Proliferative responses of Th3 clones



Kinetics of IL-10 production by Th3 clones

